PANACEABIO · NSE
Panacea Biotec Limited
₹335.95
-4.79% (-₹16.9)
Prev. close
₹352.85
Volume
1,33,412
Delivery %
52.6%
As of
20 Nov 2026
Price history
Analyst sentiment
No analyst stances in this range
0 analyst stances · last 90 days · one per analyst
Try a wider range.
Explore by date range →Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Panacea Biotec, recommending to buy above ₹431 with a stop loss at ₹405 and targets between ₹475-490. The sto…” | Raja VenkatramanNeoTrader | Panacea Biotec Ltd | HIT | |
| “Recommends buying PANACEABIO above ₹431, with a stop loss at ₹405 and targets of ₹475-490. The stock is identified as a …” | Raja VenkatramanNeoTrader | Panacea Biotec Ltd | PENDING |
Fundamentals
About Panacea Biotec Limited
Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. The company operates through Vaccines and Pharmaceutical Formulations & Nutrition segments. Its product portfolio includes prescription products in various therapeutic areas, such as diabetes, gastro-intestinal care, nephrology, oncology, orthopedics, pain management, and fever; cold and cough; and betacoronavirus, SARS-CoV-2, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, and Mpox, etc. The company also offers health supplement products; and nutrition products under the ChilRun full, ChilRun 7+, and ChillRun No Sucrose brands. In addition, it engages in the real estate business. It exports its products to approximately 50 countries. It has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, and Sputnik-V; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Rajesh Jain Ph.D.
Headquarters
New Delhi
Employees
2,102
Website
panaceabiotec.comExchange
View on NSE ↗Key stats
Market cap
₹2,107.06 Cr
Dividend yield
0.00%
EPS (TTM)
₹-1.16
Beta (1Y · daily vs NIFTY 50)
1.08
Beta (5Y · monthly vs NIFTY 50)
1.25
Shares float
1.66 Cr
EPS · quarter ended Jun 2026
₹0.38
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Debt/equity omitted where reported equity was zero or negative. Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹624.81 Cr | ₹661.23 Cr | ₹459.95 Cr | ₹559.17 Cr | ₹492.60 Cr | ₹639.77 Cr | |
EBITDA | ₹86.62 Cr | ₹1,673.32 Cr | ₹56.36 Cr | ₹41.77 Cr | ₹30.74 Cr | ₹31.74 Cr |
| ₹-147.65 Cr | ₹1,077.91 Cr | ₹-33.24 Cr | ₹-1.17 Cr | ₹-8.37 Cr | ₹-5.37 Cr | |
Diluted EPS | ₹-24.11 | ₹175.98 | ₹-5.43 | ₹-0.19 | ₹-1.37 | ₹-0.88 |
Depreciation & amortisation has filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,177.53 Cr | ₹1,758.87 Cr | ₹1,271.16 Cr | ₹1,240.68 Cr | ₹1,289.75 Cr | ₹1,262.17 Cr | |
| ₹819.53 Cr | ₹34.16 Cr | ₹20.22 Cr | ₹15.00 Cr | ₹15.00 Cr | ₹15.00 Cr | |
Stockholders' equity | ₹-228.69 Cr | ₹876.64 Cr | ₹843.61 Cr | ₹842.05 Cr | ₹834.79 Cr | ₹834.84 Cr |
Trade receivables, CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹106.76 Cr | ₹-108.43 Cr | ₹-423.46 Cr | ₹3.47 Cr | ₹-27.37 Cr | ₹16.68 Cr | |
Investing cash flow | ₹-47.68 Cr | ₹1,282.57 Cr | ₹430.33 Cr | ₹6.66 Cr | ₹64.98 Cr | ₹-40.49 Cr |
| ₹-47.11 Cr | ₹-1,175.85 Cr | ₹-18.38 Cr | ₹-2.81 Cr | ₹-2.66 Cr | ₹-1.05 Cr | |
Capital expenditure | — | ₹-17.51 Cr | ₹-40.95 Cr | ₹-82.88 Cr | ₹-50.31 Cr | ₹-54.09 Cr |
End cash position | ₹52.08 Cr | ₹50.35 Cr | ₹39.85 Cr | ₹47.17 Cr | ₹82.13 Cr | ₹57.31 Cr |
Depreciation & amortization, Debt issued, Debt repaid, Capital expenditure have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Mar 24(11Q) | Jun 24 | Sep 24 | Dec 24 | Mar 25–Jun 26(6Q) |
|---|---|---|---|---|---|
| Promoter | 73.59% | 73.46% | 72.87% | 72.49% | 72.48% |
| Public | 26.41% | 26.54% | 27.13% | 27.51% | 27.52% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Panacea Biotec Limited | ₹2,045.64 Cr | ₹344.8 | — | 2.45 | -0.6% | 0.02 | +23.8% | -20.2% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Panacea Biotec's (NSE:PANACEABIO) Earnings Are Weaker Than They Seem
Simply Wall St · 17 hours ago
Pharma sector stocks today, November 18: Indoco Remedies jumps 11.17%, Glenmark Pharma gains 1.35%; Panacea Biotec down 1.36%
Business Upturn · 5 days ago